IV Ketamine Side Effects and Safety

The dissociative, dreamlike state described in our first-infusion guide is an expected part of the treatment, not a side effect in the usual sense — it is part of how the medication produces its clinical effect. Beyond that, the most commonly reported effects include nausea, dizziness, blurred vision, and mild confusion, generally resolving within the recovery window after infusion. [Short 2018]

Ketamine transiently raises blood pressure and heart rate. This is a well documented, expected pharmacological effect, and it is the direct reason full vitals — blood pressure, heart rate, and oxygen saturation — are checked before your infusion begins and again after it ends, with heart rate and oxygen saturation monitored continuously throughout (see the first-infusion guide for the full monitoring process). These cardiovascular changes are generally transient, typically resolving within about two hours of the infusion. [Schak 2016] This is also why a pre-existing cardiovascular condition, particularly uncontrolled hypertension, is something to discuss openly at your intake — it directly affects whether and how treatment is approached.

Beyond the expected dissociative experience, some patients report transient anxiety or, less commonly, more pronounced psychotomimetic effects during an infusion. These are generally short-lived and resolve as the medication wears off. A personal or strong family history of psychosis or schizophrenia is a significant consideration in whether ketamine treatment is appropriate at all, since NMDA receptor antagonists can be higher-risk in that population [Sanacora 2017] — this is exactly the kind of history your intake is designed to surface.

Ketamine-related bladder irritation and, in severe chronic cases, cystitis, is a documented concern [Short 2018] — but it is overwhelmingly associated with high-frequency, high-dose recreational use over months or years, not the low-dose, infrequent dosing schedule used in a clinical induction series and maintenance plan. It is still something to watch: if you notice new urinary symptoms — urgency, frequency, discomfort — during your course of treatment, that is worth reporting rather than dismissing.

Ketamine is a Schedule III controlled substance under the Controlled Substances Act, reflecting a real, established potential for misuse and dependence at recreational patterns of use. This is a core reason treatment is administered in a monitored clinical setting under a physician-directed plan rather than as a take-home medication — the setting and oversight are part of the safety profile, not incidental to it. Your intake includes a review of substance use history as part of determining whether treatment is appropriate.

Certain medications and substances can interact with ketamine in ways that matter clinically, and some may need to be timed or adjusted around treatment. A full medication review — prescriptions, over-the-counter products, and supplements — is part of every intake. Bring a complete list, and tell the care team about any change between sessions.

The largest systematic review of ketamine safety in depression treatment identified a genuine gap: most available studies focus on single or short-term dosing, with comparatively little data on long-term safety after repeated infusions over months or years — even though such effects are documented in other populations exposed to ketamine repeatedly, such as chronic pain patients and recreational users. [Short 2018] This is a real limitation of the current evidence base, not something specific to any one clinic, and it is part of why ongoing monitoring throughout a course of treatment matters, rather than only at the first visit.

Short-term, single-session safety at sub-anesthetic doses is reasonably well characterized: the effects are real, mostly transient, and manageable in a monitored setting. Long-term safety with repeated dosing over years is less well characterized, and no responsible source should tell you otherwise.

The practical response to both facts is the same — honest screening at intake, monitoring during every infusion, and reporting anything new between sessions.